Sanofi began in 1973 with ten people and an unlikely parent: the French oil group Elf Aquitaine. Half a century, several mergers and a pharmacy shelf's worth of brand names later, the company has arrived at a strangely similar moment. It is simplifying again. The consumer-health business that sold Gold Bond, Allegra and Doliprane became the independently run Opella in 2025. What remained was less familiar to shoppers and more consequential to Sanofi's future - a research-led company built around prescription medicines, vaccines and the immune system.
That distinction matters because the contact attached to this profile carries a Gold Bond title. It is a useful fossil from Sanofi's recent past. Gold Bond now sits with Opella, while Sanofi has declared itself an R&D-driven, AI-powered biopharma. Its chosen ground spans immunology and inflammation, vaccines, rare diseases, neurology and oncology. The portfolio still contains established diabetes and cardiovascular medicines, but the growth thesis has shifted toward specialty drugs with clearer biological targets and toward prevention at population scale.
One immune system, many doors
The central idea is “immunoscience,” Sanofi's term for studying immune pathways without treating the borders between diseases as sacred. A signal involved in eczema may illuminate asthma. A mechanism first investigated in inflammation may matter in neurology or rare disease. The premise is not that every illness is an immune disorder. It is that the immune system supplies reusable knowledge, targets and development tools across a broad portfolio.
Dupixent is the proof that makes the thesis credible. Developed with Regeneron, the antibody blocks signaling from interleukin-4 and interleukin-13, two drivers of type 2 inflammation. It began in atopic dermatitis and expanded across asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis and chronic obstructive pulmonary disease, among other indications. In 2025 it generated roughly €15.7 billion for Sanofi, 36 percent of company sales. In the second quarter of 2026 alone, sales reached €5.2 billion.
“A blockbuster is not merely a product. It is a map of adjacent biology - and a very large bill for finding the next map.”
That success is both engine and exposure. Sanofi now expects Dupixent to approach €25 billion in annual sales by 2030 at constant exchange rates. Few companies would object to such a problem, but dependence concentrates patent, regulatory and competitive risk. The practical assignment for Sanofi is to use today's cash flow to create several tomorrow-sized businesses before the economics of Dupixent change.
Two businesses sharing one laboratory coat
Sanofi sells to two very different worlds. Specialty medicines reach patients through physicians, hospitals, pharmacies, wholesalers, insurers and national health systems. Vaccines add ministries of health, public tenders and mass immunization programs. One side may involve a specialist matching a biologic to a single patient's disease. The other may involve producing, shipping and timing millions of doses before an influenza or RSV season begins.
Immunology
Dupixent and Kevzara anchor a portfolio aimed at inflammatory diseases, with acquired rare-immunology assets adding new growth paths.
Vaccines
Influenza, meningitis, pediatric and travel vaccines sit beside newer RSV and COVID-19 prevention products.
Rare disease
Enzyme-replacement heritage meets newer hemophilia and immune-mediated medicines such as ALTUVIIIO, Qfitlia and Wayrilz.
Neurology + oncology
Multiple-sclerosis programs and Alzheimer’s research share attention with Sarclisa and a more selective cancer pipeline.
The products solve different problems, but the company sells a common promise: alter a disease's course, manage a chronic condition or prevent an infection before it starts. Beyfortus, developed with AstraZeneca, is a clean example. It is a long-acting antibody given to infants to reduce RSV lower respiratory tract disease. ALTUVIIIO, partnered with Sobi, offers once-weekly factor VIII replacement for hemophilia A. Tzield can intervene in type 1 diabetes rather than simply manage glucose after disease progression. Sarclisa Escena's on-body injector changes the administration of an established multiple-myeloma treatment - a reminder that delivery can be meaningful innovation too.
The moat is a system, not a molecule
No drug stays unchallenged. Patents expire, biosimilars arrive, standards of care improve and regulators can say no. Sanofi competes with Roche, Novartis, AbbVie, AstraZeneca, Eli Lilly, Pfizer, Merck, Johnson & Johnson and Bristol Myers Squibb, then meets GSK, Moderna and CSL again in vaccines. Its defense is the system around the molecule: disease knowledge, trial infrastructure, regulatory experience, market access, partnerships and the ability to manufacture complex products without drama.
Manufacturing is the least glamorous part of the pitch and one of the hardest to copy. Sanofi operates 37 production sites and makes roughly two billion doses of medicines and vaccines each year. It invests more than €1 billion annually in modernizing and digitizing that network. Its Modulus facilities in France and Singapore use modular rooms, continuous processing and automation to make as many as four vaccines or biologics at once, then switch production platforms in days rather than months.
AI is being pushed into the same operational frame. CodonBERT, a language model trained on 10 million mRNA sequences, has cut mRNA design time by 50 percent, according to Sanofi. Target-discovery engines produced seven new drug targets in a year. Launch units aim to remove twelve months from the path to market for priority molecules. The interesting unit is not “number of AI projects.” It is time removed from a process, targets that survive laboratory validation and batches released reliably.
The company does not plan to build every capability itself. Regeneron supplies a durable antibody partnership. AstraZeneca shares the Beyfortus story. OpenAI and Formation Bio are working with Sanofi on software across drug development. Recursion contributes computational discovery. Novavax adds a protein-based COVID-19 vaccine and the possibility of flu-COVID combinations. Acquisitions add whole pockets of biology: Blueprint Medicines brought Ayvakit and a rare-immunology pipeline; Vigil Neuroscience added an experimental Alzheimer’s program.
Sanofi's playbook is portable: narrow the portfolio, define the scientific platform, buy missing expertise, measure technology in cycle time and design production for the next product - not only the current one.
Focus also means stopping
The less flattering side of drug development is attrition, and 2026 supplied it. Sanofi chose not to seek global approval for amlitelimab in atopic dermatitis, despite positive studies, and discontinued development programs for itepekimab and balinatunfib. The decisions followed a leadership change: physician and former Merck chief Belén Garijo became Sanofi's CEO in May, then began an accelerated review of execution and R&D priorities.
A pipeline cut can mean weak evidence, insufficient differentiation, poor economics or simply a better use for the next euro. From outside, the details are rarely complete. What is clear is that an immunology strategy cannot mean advancing every immunology asset. If “focus” has teeth, it should occasionally leave bite marks.
So far, the commercial base gives Garijo room to choose. Second-quarter 2026 sales grew 17.8 percent at constant exchange rates, led by Dupixent and newer medicines including Ayvakit, ALTUVIIIO and Sarclisa. Sanofi raised full-year sales guidance to around 10 percent growth at constant exchange rates. It also expanded MenQuadfi in Europe to infants from six weeks of age, while the Impact medicine portfolio reached 30 underserved countries.
Where Sanofi fits now
Sanofi sits between the breadth of old big pharma and the concentration of a specialist biotech. It has global commercial and manufacturing scale, but it wants the scientific identity of an immunology company. It sells products as precise as an enzyme replacement for a rare disorder and as broad as seasonal vaccine protection. That combination gives it access to individual treatment decisions and national public-health systems - two markets with different clocks, buyers and risks.
The company is not uniquely using AI, buying biotech or reorganizing around specialty care. Nearly every large competitor can say some version of the same. The difference will be visible only in outcomes: faster experiments, fewer low-value trials, reliable supply, approvals that matter to practice and a portfolio less dependent on one franchise. Sanofi's advantage is plausible, not preordained.
The old Sanofi accumulated scale through a long family tree of laboratories, mergers and acquisitions. The new Sanofi is trying to make that scale feel deliberate. It has kept the complicated work, handed off the familiar shelf brands and placed its wager on a network of immune pathways that most people will never see. For patients, the useful result would be simple: a vaccine before infection, a medicine before irreversible damage and fewer years between a good idea and the day it reaches a clinic.